MetaCap

Enlivex (ENLV) vs Lakewood-Amedex Biotherapeutics (LABT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lakewood-Amedex Biotherapeutics is the larger company by market cap ($2.2 million vs $2.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENLV+242.69%LABT-71.18%
+824%+351%-121%
Oct 7, 20261 yearNov 20, 2026
ENLV+313.39%LABT-68.69%
+635%+263%-108%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENLV versus LABT key metrics
MetricENLVLABT
Share price$1.05$0.2449
Market cap$2.01M$2.19M
1-day change-11.76%+15.03%
P/E ratio (TTM)0.00—
EPS (TTM)$7,904.00$-5.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$1.24B—
52-week high$434.40$98.20
52-week low$1.00$0.17
Distance from 52-week high-99.76%-99.75%
Analyst consensusnonestrong_buy
Avg. price target upside+7519.05%+4799.96%
Average volume73.14K16.14M
Shares outstanding1.91M8.95M
Employees345
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enlivex

ENLV stock →

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

About Lakewood-Amedex Biotherapeutics

LABT stock →

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

ENLV vs LABT FAQ

Which is bigger, Enlivex or Lakewood-Amedex Biotherapeutics?

Lakewood-Amedex Biotherapeutics (LABT) is larger, with a market capitalization of $2.19M compared with $2.01M for Enlivex (ENLV).

Are Enlivex and Lakewood-Amedex Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons